MTOR and breast carcinoma: These studies have provided information about permanent changes in the genome of breast cancer cells that cause resistance to endocrine treatment, such as constitutively activating ERα mutations in patients after treatment with multiple lines of endocrine therapy [15,16,17], or constitutively activating mutations in the PI3K/Akt/mTOR signaling pathway [7].